In 2023, OncoSil focused on regulatory and ethics approvals, and site training in over eighteen (18) hospitals that are fully trained to treat patients using the OncoSil device. Commercial progress was seen in Spain with a total of 7 hospitals already performing commercial treatments, and a further 3 hospitals were trained to begin treating patients. The first ten patients were equally treated in Spain using the OncoSil device and other commercial agreements have been completed in the region of Catalunya and the Canary Islands, where hospitals with the necessary infrastructure can perform the treatment.
OncoSil Medical Capital Raise and Investor Opportunities
OncoSil (ASX: OSL) capital raise is an opportunity for investors to support the company’s clinical trials and commercialisation efforts across the world. As treatment is being rolled out in hospitals across Europe, Israel, and Turkey, it is essential to further advance adoption across other jurisdictions to support the share price over the long run.
Accelerating Commercialisation of The OncoSil Device
The OncoSil device is increasingly used in hospitals. However, Oncosil (ASX: OSL) must invest more in sales and marketing to accelerate the adoption of its device across hospitals and equally train doctors on how to use it to treat patients with pancreatic cancer.
The U.S. is an important market for cancer drugs as advanced economies in North America and Europe have an aging demographic and equally have the means to afford treatment via Oncosil (ASX: OSL).
Meanwhile, regarding GBA, t. A total of 84 hospitals now have the required status but may not possess the requisite infrastructure. However, there are about 35-45 hospitals that have the right teams and infrastructure to be able to deliver the treatment.
Partnerships and Market Expansion in Saudi Arabia
Furthermore, Oncosil has signed a distribution agreement with the Abdullah Fouad Group that has over 75 years worth of local market experience. Abdulla Fouad Group (AFG) is a dynamic and diversified business group that continues to play a pivotal role in the Kingdom’s progress to this day with over 75 years worth of experience serving the Oil & Gas, Energy, Healthcare, Information Technology, Consumer, and Construction sectors. Meanwhile, Saudi Arabia’s national healthcare system provides free universal healthcare coverage through several government agencies. There is also a growing role and increased participation from the private sector in the provision of health care services, which could support the adoption of the Oncosil device.
Global Presence and Revenue Growth
In the past, when Oncosil (ASX: OSL) has expanded into new markets, its revenues have grown in turn. As such, the expansion into Saudi Arabia will improve its revenues as its product becomes increasingly adopted in healthcare centers.
Oncosil (ASX: OSL) expansion into Germany and Saudi Arabia will further increase access to its treatment across Europe. We can expect Oncosil’s revenues to grow over the coming years as treatment expands across Europe, the Middle East, and other parts of the world. This continued expansion justified why the CEO, Nigel Lange, said he expects Oncosil to break even in late 2025 or 2025.
